Get the Stockscreener App
2.66
2.56%
-0.07
Pre-market:
2.66
C 4 Therapeutics Inc stock is traded at $2.66, with a volume of 482.98K.
It is down -2.56% in the last 24 hours and up +18.75% over the past month.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
See More
Previous Close:
$2.73
Open:
$2.74
24h Volume:
482.98K
Relative Volume:
0.34
Market Cap:
$189.31M
Revenue:
$20.76M
Net Income/Loss:
$-132.49M
P/E Ratio:
-0.9963
EPS:
-2.67
Net Cash Flow:
$-108.55M
1W Performance:
-2.21%
1M Performance:
+18.75%
6M Performance:
+21.46%
1Y Performance:
-58.50%
1-Day Range:
$2.645
$2.74
1-Week Range:
$2.57
$2.75
52-Week Range:
$1.085
$7.22
C 4 Therapeutics Inc Stock (CCCC) Company Profile
Name
C 4 Therapeutics Inc
Sector
Industry
Phone
(617) 231-0700
Address
490 ARSENAL WAY, WATERTOWN
Compare CCCC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CCCC
C 4 Therapeutics Inc
|
2.66 | 187.89M | 20.76M | -132.49M | -108.55M | -2.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Dec-19-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-18-24 | Initiated | Stephens | Equal-Weight |
| Jan-29-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-13-23 | Upgrade | Stifel | Hold → Buy |
| Feb-24-23 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-24-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-04-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Underweight |
| Apr-28-22 | Initiated | Credit Suisse | Underperform |
| Apr-11-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-10-22 | Initiated | JP Morgan | Overweight |
| Feb-11-22 | Resumed | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Nov-23-21 | Initiated | BofA Securities | Buy |
| Oct-14-21 | Initiated | SVB Leerink | Mkt Perform |
| Sep-30-21 | Initiated | Stifel | Hold |
| Jun-04-21 | Initiated | H.C. Wainwright | Buy |
| Mar-31-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Oct-27-20 | Initiated | BMO Capital Markets | Outperform |
| Oct-27-20 | Initiated | Jefferies | Buy |
View All
C 4 Therapeutics Inc Stock (CCCC) Latest News
Jacobs Levy Equity Management Inc. Purchases Shares of 697,653 C4 Therapeutics, Inc. $CCCC - MarketBeat
Fulcrum Therapeutics reports inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Travere Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
192,424 Shares in C4 Therapeutics, Inc. $CCCC Bought by Nuveen LLC - MarketBeat
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 10, 2025 - BioSpace
Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Market reaction to C4 Therapeutics Inc.’s recent newsMarket Performance Summary & Accurate Trade Setup Notifications - Newser
C4 Therapeutics Inc. Included in Top Momentum ScanJuly 2025 Sentiment & Weekly High Return Stock Opportunities - beatles.ru
C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives $8.00 Consensus Target Price from Brokerages - MarketBeat
C4 Therapeutics Inc. Breakout Confirmed by Volume MetricsQuarterly Profit Review & Community Verified Trade Signals - beatles.ru
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Is C4 Therapeutics Inc. forming a bottoming baseDollar Strength & AI Enhanced Execution Alerts - Newser
Can C4 Therapeutics Inc. recover in the next quarterEarnings Recap Summary & AI Driven Stock Movement Reports - Newser
Historical volatility pattern of C4 Therapeutics Inc. visualizedJuly 2025 Selloffs & AI Enhanced Trading Alerts - Newser
Machine Learning Models Forecast C4 Therapeutics Inc. UptickPortfolio Growth Summary & Daily Stock Momentum Reports - beatles.ru
Will C4 Therapeutics Inc. benefit from seasonalityWeekly Trading Summary & Daily Volume Surge Signals - خودرو بانک
What is C4 Therapeutics Inc.’s book value per shareEarnings Recap Report & Precise Trade Entry Recommendations - خودرو بانک
What is the dividend yield of C4 Therapeutics Inc.July 2025 Summary & Safe Entry Point Identification - خودرو بانک
Can C4 Therapeutics Inc. sustain its profitability2025 Trading Volume Trends & Verified Stock Trade Ideas - خودرو بانک
Can C4 Therapeutics Inc. weather a recessionQuarterly Risk Review & Weekly High Return Forecasts - خودرو بانک
Vera Therapeutics announces inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
Oric Pharmaceuticals reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Syndax Pharmaceuticals reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Biogen’s IND for BIIB-142 accepted by FDA - BioWorld MedTech
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics, Inc. (NASDAQ:CCCC) Held Back By Insufficient Growth Even After Shares Climb 33% - simplywall.st
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Chart overlay techniques for tracking C4 Therapeutics Inc.Trade Volume Report & Short-Term Trading Opportunity Alerts - Newser
Real time breakdown of C4 Therapeutics Inc. stock performanceQuarterly Market Review & Verified Technical Trade Signals - Newser
Visual trend scoring systems applied to C4 Therapeutics Inc.July 2025 Sector Moves & Growth Focused Entry Reports - Newser
How to integrate C4 Therapeutics Inc. into portfolio analysis toolsJuly 2025 Gainers & Comprehensive Market Scan Reports - Newser
Does C4 Therapeutics Inc. show high probability of reboundJuly 2025 Levels & Accurate Intraday Trading Signals - Newser
Building trade automation scripts for C4 Therapeutics Inc.2025 Performance Recap & Comprehensive Market Scan Insights - Newser
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Biogen Inc. shares fall 2.38% intraday as C4 Therapeutics highlights recent achievements in Biogen. - AInvest
C4 Therapeutics (CCCC) Receives Buy Rating from Guggenheim | CCC - GuruFocus
Why is C4 Therapeutics Inc. stock going downJuly 2025 Price Swings & Low Risk High Reward Trade Ideas - خودرو بانک
C4 Therapeutics shares rise 1.95% premarket after Biogen's IND application for IRAK4 degrader accepted by FDA. - AInvest
Biogen's IND Application Accepted by FDA for C4 Therapeutics' Treatment of Autoimmune Diseases - AInvest
C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration - GlobeNewswire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
C4 Therapeutics stock initiated with Buy rating at Guggenheim on myeloma drug potential - Investing.com
What the charts say about C4 Therapeutics Inc. todayJuly 2025 Closing Moves & Stepwise Entry and Exit Trade Signals - Newser
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 3, 2025 - BioSpace
How hedge fund analytics apply to C4 Therapeutics Inc. stockStop Loss & Short-Term High Return Strategies - Newser
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C 4 Therapeutics Inc Stock (CCCC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):